Clinical trial
Amlodipine as add-on to Olmesartan in Hypertension
NCT00220220 · Sankyo Pharma Gmbh, Industry · Completed
Key facts
| NCT number | NCT00220220 |
|---|---|
| Title | Amlodipine as add-on to Olmesartan in Hypertension |
| Official title | Efficacy and Safety of Amlodipine Used as add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy |
| Lead sponsor | Sankyo Pharma Gmbh, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Essential Hypertension |
| Intervention type | Drug |
| Interventions | olmesartan medoxomil, amlodipine |
| Enrollment | 429 |
| Start date | Apr 1, 2005 |
| Completion | Apr 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 24, 2018 |
| Countries | Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: